Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
Not Applicable (2)
P 1 (2)
P 2 (2)

Trial Status

Recruiting4
Not Yet Recruiting3
Enrolling By Invitation1

Clinical Trials (8)

Showing 8 of 8 trials
NCT07566897Phase 1Not Yet Recruiting

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

NCT06655142Not ApplicableNot Yet Recruiting

OSCAR II STUDY - The ONCObind CTC Removal Study

NCT07463599Phase 1RecruitingPrimary

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07224724Recruiting

Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases

NCT05705492Phase 2Recruiting

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT07334587Not ApplicableEnrolling By InvitationPrimary

Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma

NCT07150403Phase 2Not Yet RecruitingPrimary

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

NCT07043387RecruitingPrimary

Streamlining Radioembolization for CCC and Metastatic Liver Cancer

Showing all 8 trials

Research Network

Activity Timeline